Stamou Sotiris C, Boyce Steven W, Cooke Richard H, Carlos Brian D, Sweet Leslie C, Corso Paul J
Section of Cardiac Surgery, Washington Hospital Center, Washington, DC 20010, USA.
Am J Cardiol. 2002 Jun 15;89(12):1365-8. doi: 10.1016/s0002-9149(02)02348-2.
Long-term outcomes after coronary artery bypass graft surgery (CABG) plus transmyocardial revascularization (TMR) are largely unknown. We report the results of 30-day and 3-, 6-, and 12-month clinical follow-up after CABG plus TMR in a consecutive series of patients with refractory angina pectoris and > or = 1 myocardial ischemic area not amenable to CABG. All patients who underwent CABG plus TMR (n = 169) (mean age 63 +/- 10 years, 70% men, 51% with previous CABG, 82% were deemed inoperable at other heart surgery centers due to small vessels or diffuse disease) between March 1996 and February 2000 were clinically followed and end points of interest (survival, stroke, acute myocardial infarction, and revascularization) and angina class were recorded at 30 days and 3, 6, and 12 months after CABG. At 1 year, actuarial survival and event-free survival were 85% and 81%, respectively. At the end of the first year after the procedure, 7 patients (4%) had angina class III/IV versus 152 patients (90%) at baseline (p <0.001). Predictors of major adverse cardiac events were advanced age (odds ratio [OR] 3.4, 95% confidence intervals [CI] 1.2 to 9.4, p = 0.01), prolonged intensive care unit stay (OR 3.3, CI 1.1 to 9.7, p <0.001), new-onset atrial fibrillation (OR 2.8, CI 1.1 to 7.0, p = 0.02), and in-hospital myocardial infarction (OR 1.5, CI 1.3 to 1.7, p <0.001). Thus, procedural success at 30 days and overall event-free and actuarial survival in a high-risk population setting shows that CABG plus TMR is a safe revascularization option for patients with intractable angina pectoris.
冠状动脉旁路移植术(CABG)联合心肌激光血运重建术(TMR)后的长期预后情况在很大程度上尚不清楚。我们报告了一系列连续性难治性心绞痛且存在≥1个不适合行CABG的心肌缺血区域的患者在接受CABG联合TMR后30天以及3、6和12个月的临床随访结果。1996年3月至2000年2月期间所有接受CABG联合TMR的患者(n = 169)(平均年龄63±10岁,70%为男性,51%曾接受过CABG,82%因血管细小或弥漫性病变在其他心脏手术中心被认为无法手术)均接受临床随访,并记录CABG术后30天以及3、6和12个月时的关注终点(生存、中风、急性心肌梗死和血运重建)及心绞痛分级。1年时,精算生存率和无事件生存率分别为85%和81%。在手术第一年结束时,7例患者(4%)为Ⅲ/Ⅳ级心绞痛,而基线时为152例患者(90%)(p<0.001)。主要不良心脏事件的预测因素为高龄(比值比[OR] 3.4,95%置信区间[CI] 1.2至9.4,p = 0.01)、重症监护病房停留时间延长(OR 3.3,CI 1.1至9.7,p<0.001)、新发房颤(OR 2.8,CI 1.1至7.0,p = 0.02)以及住院期间心肌梗死(OR 1.5,CI 1.3至1.7,p<0.001)。因此,在高危人群中30天的手术成功率以及总体无事件生存率和精算生存率表明,CABG联合TMR对于难治性心绞痛患者是一种安全的血运重建选择。